The deck opens with a title slide and a forward-looking statement, followed by an introduction from CEO Stéphane Bancel. He explains mRNA as an information molecule and describes Moderna's platform approach, built on mRNA science, delivery science and manufacturing. The deck then sets out the modality model and three areas of focus: infectious disease vaccines, individualized cancer treatments and rare genetic liver diseases. Stephen Hoge leads the business strategy section, covering 2026 revenue drivers and the 2027 growth outlook. Juan Andres then presents manufacturing, including the Marlborough site. Jamey Mock covers financials, with a review of 2025 objectives, a 2026 report card and new midterm objectives. A coffee break separates the business section from infectious disease vaccines, where Rituparna Das presents real-world evidence studies showing vaccine effectiveness data from several U.S. databases. The deck closes with business and clinical Q&A, a manufacturing site tour, and a conclusion by the CEO. Slides use a consistent red headline style, one idea per slide and simple diagrams.
Slides worth studying
- Slide 6: A side-by-side comparison of a binary computer and the four-letter mRNA code makes the central analogy clear at a glance.
- Slide 44: The objective review builds the 2026 report card one line at a time, so each goal is revealed as its own step.
- Slide 52: Operating levers for infectious disease profitability are arranged as a clear metric panel with the key driver listed beneath each number.
Details
- Company: Moderna
- Year: 2026
- Type: Investor presentation
- Industry: Biotechnology
- Pages: 183
The hosted copy of this deck is being prepared. Newsletter readers will find the download here.
Review score: 8 out of 10, Strong
Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.
The deck's strength is wayfinding across a very long document: an agenda with speakers on slide 14, section dividers, a left-hand progress rail through the growth drivers on slides 17 to 23 (slide 18 highlights "mFLUSIVA 2027"), and a numbered study navigator repeated before each real-world study (slides 70, 74, 78). The financial section separates results from targets with care: slides 44 to 48 review last year's objectives one at a time and build a "2026 report card" that gains a line per slide (slide 44: "2026 revenue growth of 15-25% expected to exceed original framework of up to 10%"), and slide 52 states "2026 expectations" with footnoted definitions. Evidence slides carry their own limits, as on slide 67 ("Study limitations") and the forest plots that follow a fixed design, population, result, limitations, takeaways order. The bottleneck is length and repetition: the real-world evidence block from slide 61 to slide 109 repeats the same five-slide pattern for each study with takeaway slides that are prose in boxes (slides 84 and 100), and slide 44 pastes a whole earlier slide, with its own title and logo, inside the page. Pages 121 to 183 were not seen on contact sheets, apart from slide 133 at readable size, so the oncology section and the conclusion are unreviewed.
Worth keeping: Keep the report card device on slides 44 to 48, where each prior objective is shown against what happened before new objectives are set on slide 50.
Most useful repair: Condense the real-world evidence block (slides 61 to 109) by moving baseline characteristics tables such as slides 65, 72, 76 and 80 to an appendix and replacing the prose takeaway pages (slides 68, 84, 91, 100, 105) with the summary chart on slide 83.
What would change the score: Seeing pages 121 to 183 could move the score either way, since only 12 of 183 pages were read at readable size and the oncology section and conclusion were not inspected.
Confidence medium. 120 of 183 pages inspected on contact sheets, 12 at readable size. Reviewed 2026-11-15. Model-assisted review (claude-fable-5-2, in session).
Full text of the slides (183 slides)
Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.
Slide 1
Analyst Day 2026 / November 12, 2026 / © 2026 Moderna, Inc. All rights reserved.
Visuals: Three line icons in circles, left to right: (1) a blue cross above a red open hand, a medical/care icon; (2) a red arrow and a blue diagonal line with red arrows rising, a growth/trend icon; (3) a red wavy line over three short blue vertical ticks, a DNA/strand-like icon. Each icon is a thin blue (#29ABE2 approx.) circle outline about 7.5% wide with the glyph inside in red #E31837 or blue. Bottom-right: the moderna wordmark in red #E31837 lowercase letters with a row of short light-to-mid blue dashes (#29ABE2 approx.) beneath it. No photographs; no overlays.
Slide 2
Forward-looking statement
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements
regarding: the potential of Moderna's mRNA platform; Moderna's ability to execute on its next phase of growth and its mid-term financial strategy; Moderna's use of
AI and automation to accelerate innovation and increase productivity; Moderna's 2026 financial framework, including 15-25% revenue growth, gross margin
expansion, cost reductions, and liquidity; Moderna's expected growth drivers in 2027 and beyond; Moderna's ability to improve infectious disease vaccine franchise
profitability; Moderna's investment strategy, capital allocation and portfolio priorities; continued cost discipline and efficiency; the potential of intismeran, including as
the standard of care in adjuvant melanoma and its curative potential; the potential commercial launch of intismeran, subject to regulatory approval; Moderna's
commercial and manufacturing readiness for intismeran; Moderna's ability to scale manufacturing capacity efficiently; expectations regarding the size of the eligible
U.S. market for intismeran; the potential of intismeran in additional tumor types and across settings; mRNA-4194's potential in Lynch syndrome; the potential of
Moderna's broader oncology portfolio; pending and anticipated regulatory filings and potential approvals, including timing of approvals; Moderna's ability to reduce
the time from strain selection to vaccine supply; the size of the respiratory vaccination market and future demand; the RFS benefit of intismeran plus pembrolizumab
emerging over time; and anticipated progress and milestones for Moderna's pipeline programs. In some cases, forward-looking statements can be identified by
terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the
negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this
presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those
expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described
under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange
Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law,
Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new
information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this
presentation.
Financial figures in this presentation as of, and for the quarterly periods ended, September 30, 2026, and September 30, 2025, are unaudited.
2
© 2026 Moderna, Inc. All rights reserved.
Slide 3
Introduction
Stéphane Bancel
Chief Executive Officer
3
© 2026 Moderna, Inc. All rights reserved.
Visuals: Icon: a circular badge about 6.0% from the left and 28.6% from the top, about 7.0% wide and 12.5% tall, with a white ring and a red (#E31837) circle outline containing a red sine-like curve with three short cyan (#2AACE2) vertical tick marks on each side of a central dip, resembling a stylised DNA or mRNA strand. Background: a wide pale image of soft light-blue translucent wave ribbons (#F2F6F9 base, pale cyan #C9E9F6 to #DCEFF8 highlights) sweeping from bottom left to top right across the right three quarters of the slide, with soft gradient lighting and no hard edges. Logo: the red Moderna wordmark in lowercase sans-serif (red #E31837) with a registered mark, beneath which is a row of short dashes graded from pale blue to cyan (#2AACE2). Cyan thin horizontal rule about 5.8% from the left, 44% of slide width short, below the title, about 0.3% thick, colour #2AACE2.
Slide 4
mRNA is nature's information molecule, carrying instructions
to make proteins
DNA
mRNA
Protein
4
© 2026 Moderna, Inc. All rights reserved.
Visuals: Three illustrations in a left-to-right process flow connected by two light-blue right-pointing block arrows. (1) DNA: a double helix in light-blue (#5BC0EB-like, about #4FB3E8) strands with rungs made of paired base blocks reading A, T, A, T, G, C, A, G, T, A, A, T; blocks are navy #0B3C8C, red #E31837, grey #9E9E9E and blue #1F6FBF, with white letters; a pale blue circle (about #EEF6FC) sits behind the helix centre. (2) mRNA: a light-blue wavy single strand (about #4FB3E8) with upright rounded bars standing on it; left group reads A, U, G in navy, red, red bars; a raised central group reads C (grey), A (navy), G (red) with the navy middle bar tallest; right group reads U (red), A (navy), A (navy); a pale blue circle sits behind it. (3) Protein: a tangled loop of thick strokes, a blue (#1B75BC) loop and a red (#E31837) looping strand crossing each other, on a pale blue circle (about #EEF6FC). Arrows are solid light-blue (about #7CC6F0) chevron-style block arrows, each about 5% of width. Illustrations appear on a near-white background with no boxes.
Slide 5
Moderna was founded on the idea to use mRNA to create / new medicines for patients / Secreted proteins / Transmembrane proteins / Ribosome / Nucleus / Nuclear proteins / ER proteins / Mitochondrial proteins / 5 / © 2026 Moderna, Inc. All rights reserved.
Visuals: Hand-drawn black-and-grey line illustration of a cell on white. A round virus-like particle at upper left with a black arrow pointing down-right to a ribosome labelled 'Ribosome' (a small squiggle mRNA strand attached to a sphere). From the ribosome a fan of black curved arrows points outward: two upward to 'Secreted proteins' area (small green protein shapes), several to the cell membrane (a double-line curved membrane across the slide) where light-blue transmembrane protein shapes are embedded and labelled 'Transmembrane proteins', one arrow to a mitochondrion at upper right labelled 'Mitochondrial proteins' (grey outline with purple inner folds), one arrow to ER (endoplasmic reticulum, grey stacked folded membranes) labelled 'ER proteins' with light-blue protein shapes, and one arrow down to the nucleus labelled 'Nucleus' with a small blue shape labelled 'Nuclear proteins'. Faint grey mitochondria appear at lower left and right edges. Red (#E31837) hand-drawn ellipses and circles encircle 'Secreted proteins', 'Transmembrane proteins', 'ER proteins', 'Mitochondrial proteins' and 'Nuclear proteins'. Bottom-right corner has a small pixelated pink and light-cyan mosaic image, 22 by 5 pixels, about 12.2% by 4.9% of the slide, blurred. The illustration is not boxed and is cropped at its right edge around x 71%.
Slide 6
Like computers use binary code, biology uses mRNA’s four-letter
code to instruct cells
Computers use
a binary system
Life uses a
quaternary system
Adenosine (A)
Uridine (U)
Guanosine (G)
Cytidine (C)
AUG GAC GCA UCA AGG … …AUG CAU UAC UGC UAA
mRNA
Amino acid
protein chain
Coding region
5′
3′
6
© 2026 Moderna, Inc. All rights reserved.
Visuals: Left: a line-art illustration of a desktop computer monitor, dark navy outline with rounded corners, screen filled with rows of cyan (#1EB4E6-like) binary digits 0 and 1, a small circular power button on the bezel and a light grey-blue stand and base with soft blue shadow beneath. Right: four rounded pale pink (#FCEEF3) cards in a row, each showing a chemical structure drawn in purple (#6B2A7A-like) line art with nitrogen and oxygen labels: Adenosine (A) with NH2 group, Uridine (U) with O and NH groups, Guanosine (G) with O, NH and NH2 groups, Cytidine (C) with NH2, N and O groups; the letters A, U, G, C are red and the names navy. Below the cards a purple curly brace spans all four cards and points down with an arrow to an mRNA strand: a light grey cylinder with a pink highlighted coding region band containing the sequence AUG GAC GCA UCA AGG … …AUG CAU UAC UGC UAA, a bracket beneath labelled Coding region, 5′ at left end and 3′ at right end. An orange ribosome-like sphere sits on the strand near the right, with a white curved amino acid protein chain above it and a dark dot leader line to the label Amino acid protein chain. The illustration sits on a very faint off-white panel. Pixelated pink mosaic image at bottom right corner.
Slide 7
Because mRNA is an information molecule, we had the unique / opportunity to build a platform company
mRNA science
Design and engineer
mRNA instructions
Delivery science
Deliver mRNA
into cells
Manufacturing
Produce mRNA
medicines at scale
Moderna’s mRNA platform
7
© 2026 Moderna, Inc. All rights reserved.
Visuals: Background illustration (full-width, about 2.7% to 100% horizontally, 24% to 82% vertically): a thin cyan-blue (#1AAEE6 approx.) wavy line running left to right, with small open circle nodes at about x 9.4% and x 93% (ring stroke about 0.3% of width, white fill). Three light-blue (#DDF0FA approx.) filled circles sit behind three icons. Icon 1 (mRNA science): a red (#E31837) outlined circle containing a red double-helix-like wave curve with three short blue vertical tick marks on each side. Icon 2 (Delivery science): a red outlined circle with a ring of short red spikes around the edge, containing a blue sine wave. Icon 3 (Manufacturing): a red outlined circle containing a red robotic arm with a blue box/package icon and a blue accent line, on a red base. Below the icons, a blue (#1AAEE6 approx.) connector: from the bottom of icon 1 and icon 3 lines descend and curve into a horizontal line that joins at centre and continues into a downward arrowhead pointing at the red bar. Decorative strip bottom-right: a row of six adjacent rectangles in pale pinks (#F5D5DC to #E6C3CB approx.), flat, no border.
Slide 8
Our platform enables multiple modalities, each with the
potential to create families of medicines
mRNA science
By combining the
components of our mRNA
platform, we create
modalities: groups of
potential mRNA medicines
that share similar mRNA
technologies, delivery
technologies, and
manufacturing processes
to achieve shared
product features
Delivery
science
Manufacturing
processes
Proof-of-concept data from sentinel
programs de-risk modalities and can
accelerate development plans
Medicine 2
Medicine 1
Medicine 2
Medicine 1
Medicine 2
Medicine 1
Modality 1
Modality 2
Modality 3
8
© 2026 Moderna, Inc. All rights reserved.
Visuals: Diagram (left): three red-outlined white circles with icons arranged in a triangle, joined by three pale light-blue (#BDE3F5) curved double-headed arrows. Top circle (mRNA science) shows a red sine-wave strand over blue vertical tick marks (mRNA icon). Bottom-left circle (Delivery science) shows a blue virus-like spiked ring around a red sine wave. Bottom-right circle (Manufacturing processes) shows a red robotic arm with a blue box and a blue handle detail. The bottom arrow is a curved double-headed arrow connecting Delivery science to Manufacturing processes; the two upper arrows connect mRNA science to each of the bottom nodes. Centre: body text, no shape behind it. Panel (right): a white rounded rectangle with a light grey outline containing three columns of stacked overlapping circles, each column having five circles: the back circles are tinted and the front circle is labelled. Column 1 (Modality 1) runs from pale blue #C6E0F5 at the top to bright blue #00AEEF for the front circle labelled Medicine 1, with intermediate circles labelled Medicine 2 in mid blue. Column 2 (Modality 2) runs from pale grey-blue #E9EEF3 to navy #14507F for the front circle labelled Medicine 1, with Medicine 2 on a mid steel blue #6F97B8 circle. Column 3 (Modality 3) runs from pale green #EAF6E0 to green #7AC143 for the front circle labelled Medicine 1, with Medicine 2 on a mid green. Below each column is a red-outlined white circular icon: Modality 1 shows a red-outlined syringe/vial in blue and red; Modality 2 shows a blue magnifying glass over red virus particles; Modality 3 shows a blue DNA double helix. Each icon is labelled in grey below. Pink strip (bottom right): five adjoining vertical blocks of pink tints, from light #F9E1E6 to deeper #E6BFC8, no text.
Slide 9
The unique properties of mRNA create important
advantages for drug development
1
Large opportunity to
address unmet need
2
Higher efficiency in R&D
3
Rapid development
4
Greater capital efficiency
Ribosome
Nucleus
Nuclear proteins
ER proteins
Mitochondrial proteins
Transmembrane proteins
Secreted proteins
9
© 2026 Moderna, Inc. All rights reserved.
Visuals: A hand-drawn-style line illustration of a cell. A round virus-like ribosome sketch at upper left with a wavy mRNA strand leading to a ribosome labelled 'Ribosome' (grey-black line art). Black curved arrows fan out from the ribosome to five destinations: two arrows up to 'Secreted proteins' (small teal-green protein sketches), three arrows to 'Transmembrane proteins' (light-blue protein sketches embedded in the membrane line), and arrows to 'Mitochondrial proteins' (a mitochondrion outlined grey with purple inner cristae), to 'ER proteins' (light-blue protein sketch on the endoplasmic reticulum folds), and to 'Nuclear proteins' (small blue protein at the nucleus). Grey stacked elongated ER sheets and a nucleus labelled 'Nucleus' sit in the lower half; faint grey mitochondria appear at left and right edges. Red hand-drawn circles (#E31837) highlight 'Secreted proteins', 'Transmembrane proteins', 'Mitochondrial proteins', 'ER proteins' and 'Nuclear proteins'. The illustration is not boxed; it sits on white with a light grey cell membrane line across the top. Sketch style, monochrome grey with coloured accents, no shadows.
Slide 10
We are focused on areas where mRNA can deliver transformative / patient benefit
Infectious disease / vaccines
First fundamentally new vaccine / technology platform in decades
Established approaches
mRNA / platform
1900s
1980s
2000s
2020s
Egg-based / vaccines
Recombinant / proteins
Viral / vectors
RFS Primary Analysis: ITT
RFS (%)
Months
82.2% (95% CI 79.3–84.8)
70.0% (95% CI 65.0–74.5)
HR 0.58 (95% CI 0.45–0.75) / P < 0.001 (two sided)²
No. at risk
Individualized / cancer treatments
Potential to move beyond the / PD1 efficacy ceiling
Rare genetic / liver diseases
Ability to reach intracellular protein / targets other technologies cannot
Valine
Methionine
Isoleucine
Threonine
Propionic acid / (intestinal flora)
Odd-chain fatty acids
Cholesterol esters
Propionyl-CoA
3-hydroxypropionate
2-methylcitrate
Propionylcarnitine
Ammonia
Propionic Acidemia / PCC enzyme / deficiency
Active PCC / enzyme
Methylmalonyl-CoA
10
© 2026 Moderna, Inc. All rights reserved.
Visuals: Three graphics and one pink tile strip. (1) Left column: a timeline illustration with a bracket labelled 'Established approaches' above three outlined cyan circles containing an egg icon, a protein-cluster icon and a viral-vector lattice icon, labelled 'Egg-based vaccines', 'Recombinant proteins' and 'Viral vectors'; to the right a red virus icon with a blue sine wave labelled 'mRNA platform'; below, a horizontal navy timeline with open circle markers at 1900s, 1980s and 2000s, a break mark, and a dashed arrow to a solid red dot at 2020s. (2) Centre column: a Kaplan-Meier chart on a white card with soft grey drop shadow, titled 'RFS Primary Analysis: ITT'. Y axis 'RFS (%)' 0 to 100 in steps of 10; X axis 'Months' 0 to 35 with ticks at 0, 6, 12, 18, 24, 30, 35. Two step curves: green (Imfinzi + pembrolizumab) ending about 82.2% and blue (Placebo + pembrolizumab) ending about 70.0% at 24 months, with a vertical dashed line at 24 months. Labels '82.2% (95% CI 79.3–84.8)' in green and '70.0% (95% CI 65.0–74.5)' in blue beside the curves. Embedded table headed N and Events, n (%): Imfinzi + pembrolizumab 757, 136 (18.0%); Placebo + pembrolizumab 380, 111 (29.2%). Number-at-risk rows: Imfinzi + pembrolizumab 757, 683, 646, 618, 136, 10, 0; Placebo + pembrolizumab 380, 341, 302, 282, 72, 3, 0. Footnotes in tiny grey type below and an ESMO logo at bottom right. (3) Right column: a blue line-drawn metabolic pathway diagram on a pale grey-white panel. Shapes: a mitochondrion icon with a red square marker, a gut icon labelled Propionic acid (intestinal flora), a hexagon cluster labelled Odd-chain fatty acids / Cholesterol esters; the first two connect by arrows that merge into a node icon labelled Propionyl-CoA; a red dotted arrow from that node points right to the red list 3-hydroxypropionate, 2-methylcitrate, Propionylcarnitine, Ammonia; a downward arrow leads to an enzyme blob labelled Active PCC enzyme; a red dashed arrow from left marked by a red circled X connects Propionic Acidemia / PCC enzyme deficiency to the enzyme; a downward arrow leads to Methylmalonyl-CoA and a final node icon. (4) Bottom right: a strip of five adjacent pink rectangles of differing tints.
Slide 11
Our differentiated vaccines and investigational medicines have / the potential to create durable franchises / Infectious disease / vaccines / Repeatable platform across / many pathogens / Individualized / cancer treatments / Individualized by design; / proprietary algorithm / potentially limits generics / Rare genetic / liver diseases / High unmet need; / difficult to run clinical studies / after a product is approved / 11 / © 2026 Moderna, Inc. All rights reserved.
Visuals: Three line illustrations in a consistent blue (#1A9AD6 approx.) and red (#E31837 approx.) outline style on white. (1) Infectious disease vaccines: a central red-outlined circle containing a blue squiggle (mRNA-like strand), joined by light blue dotted lines to five pathogens arranged around it: a red-outlined spiky virus at top, a blue round cell/organelle at upper left, a blue rod-shaped bacterium at upper right, a blue spiky virus at lower left and a blue spiky virus at lower right. (2) Individualized cancer treatments: a blue outline of a human upper body (head, shoulders, arms) with a small red dashed circle and solid red dot on the chest; a red line runs from the dot to a blue-outlined magnifying circle showing three DNA strands stacked vertically, in red, orange-red and blue, each with a coloured dot at its left end. (3) Rare genetic liver diseases: a cluster of about 30 blue outline person icons arranged in a rounded mass, with one red person icon in the centre enclosed by a red dashed circle. No photographs, charts or tables.
Slide 12
We invest across multiple horizons to drive near-term
growth and long-term innovation
Horizon 1
Established modalities
Late-stage pipeline
and approved products
Horizon 2
Emerging modalities
In Phase 1 or 2 clinical trials
Horizon 3
New modalities
Potential to advance to
first-in-human clinical trials
in the mid-term
Horizon 4
Inventing new technology
building blocks
To unlock future modalities
Sales
Time
AI
Data
Insights
Biology
Experimentation
Lucy
12
© 2026 Moderna, Inc. All rights reserved.
Visuals: Line chart-style illustration with no printed axis values: a thick bright-blue (#2AACE2) curve starts at bottom-left near the x-axis of the panel, rises steeply and then flattens horizontally, ending at about the boundary between Horizon 1 and Horizon 2 columns. Axes are labelled only 'Sales' (vertical, rotated, grey #A6A6A6) and 'Time' (horizontal, grey #A6A6A6); no units or numeric ranges are printed. Panel is a light grey rectangle with thin grey vertical dividers at about 36%, 66% and 85% of panel width. Image at right of Horizon 4 column: a circular diagram of the Lucy platform, a central glowing blurred cloud of red, purple and blue particles with the word 'Lucy' in bold letters, the 'L' red and 'ucy' in blue-purple gradient. Around it, four red-outlined white circular icons connected by curved blue arrows in clockwise order: top 'AI' icon (brain), right 'Data' icon (database cylinder), bottom-right 'Experimentation' icon (flask), bottom-left 'Biology' icon (DNA helix), and left 'Insights' icon (bar chart); labels AI, Data, Experimentation, Biology, Insights are in small dark text. Lighting flat, no photograph.
Slide 13
AI is accelerating innovation and transforming how we work
across Moderna
Lucy
AI-enabled ways of working
Connecting AI, automation, experimentation, and
data into a continuously improving learning system
AI, automation, and other technology to increase productivity, speed,
and adaptability across SG&A, manufacturing, and development
AI
Insights
Data
Lucy
Experimentation
Biology
SG&A
Manufacturing
Development
AI + Automation + Data + Technology
Efficiencies
Productivity
Adaptability
13
© 2026 Moderna, Inc. All rights reserved.
Visuals: Left column: illustration of a circular cycle diagram. Five red-outlined white circular nodes sit on a ring, labelled AI (top, blue brain icon), Data (right, blue database icon), Experimentation (lower right, blue flask icon), Biology (lower left, blue DNA helix icon) and Insights (left, blue and red bar chart icon). Blue arrows curve clockwise between the nodes around the ring. At the centre is a glowing, dotted particle cloud shading from red at left to blue at right and purple between, with the word Lucy in bold red-to-blue gradient letters. The background is white. Right column: diagram of boxes and arrows. Three top circles with thin light-blue outlines, labelled SG&A (blue and red people icon), Manufacturing (navy factory icon with red chimney) and Development (navy and red microscope icon). Blue elbow arrows run from SG&A and Development and down to a central arrow into a rounded pill with pale blue fill labelled AI + Automation + Data + Technology, beside a small AI chip icon, separated from the text by a vertical rule. From the pill, blue arrows branch down to three bottom circles with light-blue outlines, labelled Efficiencies (dark gear with bar chart icon), Productivity (gauge icon with red needle and blue speed lines) and Adaptability (red up arrow with left and right arrows). Labels sit below the bottom circles. Thin vertical grey divider line at about 46% of slide width, from about 20% to 85% of slide height, colour about #B0B0B0. Pink colour-block strip at bottom right: five adjoining vertical rectangles in shades from pale pink #F2D7DD to rose #E6C3CA, no outlines, not overlapping text.
Slide 14
Agenda
Introduction
Stéphane Bancel Chief Executive Officer
Business Strategy
Stephen Hoge, M.D. President
Manufacturing
Juan Andres Chief Operating Officer
Financials
Jamey Mock Chief Financial Officer
Business Q&A
Coffee Break
Infectious Disease vaccines
Real world evidence studies
Rituparna Das, M.D. Ph.D. Head, Clinical Development, Infectious Diseases,
Rare Diseases, and Therapeutics
Annual Strain Update
William Schief, Ph.D. Vice President, Protein design, Infectious Disease Research
Oncology therapeutics
David Berman, M.D. Ph.D. Chief Development Officer
Conclusion
Stéphane Bancel Chief Executive Officer
Clinical Q&A
Marlborough manufacturing site tour
14
© 2026 Moderna, Inc. All rights reserved.
Visuals: A small decorative image at bottom-right, 12.2% by 4.9% of the slide, made of six vertical blocks of pink tones, lightest pinks at the left and right ends and deeper pinks in the middle. It is a flat, unbordered colour strip with no subject. Thin red horizontal rules (about 1 px, #E31837) separate the table rows at roughly y 20.6%, 27.5%, 34.4%, 41.2%, 45.7%, 50.1%, 66.6%, 73.4%, 80.4%, 84.8% and 89.2%, spanning x 5.6% to about 86.2%. No charts, photos or logos.
Slide 15
Business Strategy
Stephen Hoge, M.D.
President
15
© 2026 Moderna, Inc. All rights reserved.
moderna
Visuals: Logo badge: a white-ringed circle with a red (#E31837) outline enclosing a stylised red sine-like curve with three small light-blue (#2AACE2) vertical tick marks above and below the curve, centred in the badge. Background photograph/illustration: soft pale blue translucent wave ribbons sweeping from lower left to upper right across the light right side, with a light blue highlight near the top right edge; the ribbons are slightly blurred and low contrast against #F2F6F9. Decorative curved edge: a bright light-blue (#2AACE2) arc stroke runs along the curved boundary of the navy panel. Moderna wordmark: lowercase 'moderna' in red (#E31837) with a small registered mark, above a row of short dashed bars in pale to bright blue (light blue to #2AACE2) under the wordmark.
Slide 16
Executing on our three-year strategy; positioned for growth
in 2027
Infectious disease vaccines
Geographic expansion
Oncology therapeutics
Rare disease therapeutics
Positioned to deliver
2026
2027
2028
PA
mRNA-4359
Intismeran
Norovirus
Flu + COVID
Flu
LATAM & APAC partnerships
EU market growth
mNEXSPIKE
UK, Can, Aus partnerships
Key developments supporting
growth in 2027
mFLUSIVA approved by the U.S. FDA
and Health Canada
mNEXSPIKE and mCOMBRIAX/mCOFLU
approved by EMA and Health Canada
Mexico and Taiwan partnership execution
Intismeran in adjuvant melanoma: Positive
Phase 3 data in adjuvant melanoma study
presented at ESMO Presidential Symposium
16
© 2026 Moderna, Inc. All rights reserved.
Visuals: One illustration: a three-year roadmap graphic with a legend at top-left, three year columns labelled 2026, 2027 and 2028 along the bottom, and a dark navy diagonal line rising from lower-left to upper-right across the columns. Each column is a light grey (#EBEBEB) rounded-bottom house-shaped panel with a white outline and a pointed top. The 2026 column holds two stacked blocks: a red block 'mNEXSPIKE' and a blue block 'UK, Can, Aus partnerships'. The 2027 column is outlined by a blue (#1CA9E6) rounded rectangle with a thin stroke, labelled by a blue checkmark-in-circle icon with a red tick and the blue text 'Positioned to deliver'; it holds, from top to bottom, a navy block 'Intismeran', a red block 'Flu', a blue block 'LATAM & APAC partnerships' and a blue block 'EU market growth'. The 2028 column holds, from top to bottom, a steel-blue block 'PA', a navy block 'mRNA-4359', a red block 'Norovirus' and a red block 'Flu + COVID'. Legend swatches top-left: red #E31837 'Infectious disease vaccines', blue #1CA9E6 'Geographic expansion', navy #1E2846 'Oncology therapeutics', steel blue #6A93C6 'Rare disease therapeutics'. Three thin dashed grey vertical dividers separate the columns. Flat vector style, no shadows, no photographs. Also a small pink mosaic image at bottom-right of six adjacent pink tiles, mostly #F2C9D2 with some #E6BCC6 and #F7E1E6, not overlapping other elements.
Slide 17
2026 revenue drivers
2026 revenue growth of 15-25% expected to exceed original framework of up to 10%
2026 revenue
outlook increased
mFLUSIVA 2027
EU product
approvals
LATAM and APAC
partnerships
Intismeran
Strategic partnerships
Multi-year partnerships providing recurring revenue
UK
Canada
Australia
Partnership features
Long-term
agreements
Supports national
security & defense
R&D
investment
Onshore
manufacturing
Majority of sales outside the U.S. will be
driven by our strategic partnerships
mNEXSPIKE
mNEXSPIKE’s share of Moderna retail sales 1
mNEXSPIKE
94%
Spikevax
6%
Real-world evidence
Real-world evidence demonstrated a consistent effectiveness
advantage for mRNA-1283 over BNT162b2 LP.8.1 in older adults
Cumulative Incidence, %
mRNA-1283 n=55,349
BNT162b2 n=239,152
Adjusted Comparative VE†, % (95% CI)
Medically-attended† (composite) 0.16 0.28 35.9%
Hospitalization 0.02 0.05 47.0%
ED/UC 0.08 0.16 35.1%
Outpatient 0.13 0.24 39.0%
Antiviral Treatment§ 0.04 0.09 40.1%
Exploratory Non-COVID-Specific Outcome
MACE§ Hospitalization 0.07 0.15 39.3%
-20% 0% 20% 40% 60% 80%
Favors BNT162b2 ◄► Favors mRNA-1283
moderna
1. Based on information licensed from IQVIA: NPA Rapid for the period w/e 9/4/2026 to 10/30/2026 reflecting estimates of real-
world activity. All rights reserved
© 2026 Moderna, Inc. All rights reserved.
17
Visuals: Donut chart: type donut, title mNEXSPIKE’s share of Moderna retail sales (superscript 1). Series: mNEXSPIKE 94% in light blue (about #5DB4EA) and Spikevax 6% in dark navy (#1E2846). No axes, no legend; labels sit to the right of the ring. Centre is a white circle holding a line-drawn syringe icon in red-pink outline. No highlighted points. Flags: three circular flag icons in a row: United Kingdom Union Jack (red, white, blue), Canada (red-white-red with red maple leaf on white centre), Australia (blue field with Union Jack canton and white stars). Icons in the partnership grid, each line-drawn in red #E31837 outline: document with check (Long-term agreements), shield with check mark (Supports national security & defense), laboratory flask with plus (R&D investment), factory with chimney (Onshore manufacturing). Sidebar icons, line-drawn white on circles: bar chart with rising arrow in white on blue circle (2026 revenue outlook increased); syringe on grey circle (mFLUSIVA 2027); EU stars circle on grey (EU product approvals); two hands shaking on grey (LATAM and APAC partnerships); person with DNA helix on grey (Intismeran). Real-world evidence screenshot: a white Moderna slide snapshot with a thin navy left edge and soft drop shadow, containing a red bold headline, a table with column headers Cumulative Incidence, % (mRNA-1283 header in blue #2AACE2 and BNT162b2 header in purple #7B4FD6, each with n counts) and a forest plot column Adjusted Comparative VE with axis from -20% to 80% and blue dot-and-whisker estimates per row, plus Favors BNT162b2 and Favors mRNA-1283 labels with a double arrow; small Moderna wordmark bottom right in red. Pink tint block bottom-right made of about six tiles in shades from #E8B4C0 to #F6E3E8.
Slide 18
2027 growth driver / mFLUSIVA 2027 launch / Limited 2026 launch strengthens 2027/28 commercial position / 2026 revenue / outlook increased / With August approval occurring after the / 2026/27 contracting cycle, the limited launch / is creating value for the next full season / AAFP recommendation as an / enhanced influenza vaccine / 110K+ shots-in-arms1 and / early market experience / Two mRNA-1010 VE studies / published in Journal of Medical / Economics2 and Vaccines3 / 2026 LIMITED LAUNCH / Stocked in over 25% of / U.S. pharmacies within the / first 3 months of launch4 / 4 / mFLUSIVA 2027 / EU product / approvals / LATAM and APAC / partnerships / Intismeran / 18 / 1. Based on information licensed from IQVIA: NPA Rapid for the period w/e 8/28/2026 to 10/30/2026 reflecting estimates of real-world / activity. All rights reserved / 2.https://doi.org/10.1080/13696998.2026.2706361 / 3.https://doi.org/10.3390/vaccines14090750 / 4.Internal data sets and Public Vaccine Access / © 2026 Moderna, Inc. All rights reserved.
Visuals: 1. Illustration of a light blue outline map of the continental United States, with Alaska and Hawaii drawn in the same style, placed at x 52.8%, y 24.0%, w 45.6%, h 58.0%. The map is drawn as thin sky-blue (#2AACE2-like) outlines on white with no fill, showing state boundaries, and it is not cropped. A translucent pale blue rectangle (#E5F5FB at 75% opacity) with slightly rounded corners overlays the central part of the map, carrying the callout text. 2. Five grey circular icons in the sidebar, each about 4.4 to 5.1% of slide width: at y 9.7% a grey circle with a white line-art bar chart and rising arrow (2026 revenue outlook); at y 29.6% a blue (#2AACE2) filled circle with a white line-art syringe (mFLUSIVA 2027, the active item); at y 46.3% a grey circle with a white line-art EU star ring (EU product approvals); at y 66.2% a grey circle with a white line-art handshake (LATAM and APAC partnerships); at y 86.2% a grey circle with a white line-art person with a DNA or hourglass figure (Intismeran). 3. Three icons beside the body points: at x 22.1%, y 39.7% a blue document icon with a red award rosette (AAFP recommendation); at x 22.1%, y 54.7% a blue syringe with a red needle tip, drawn diagonally (110K+ shots-in-arms); at x 22.7%, y 70.6% a blue document with a red bar chart (publications). 4. Two thin light grey horizontal rules, about 23.1% to 52.8% width, at about y 51.5% and y 66.5%. 5. A strip of six adjacent pink rectangles at x 86.6%, y 92.2%, w 12.2%, h 4.9%, graded from deeper rose pink on the left to very pale pink on the right, with a light pink tone at the right end. No photographs are present.
Slide 19
2027 growth driver
Approved respiratory portfolio in Europe
Company positioned to capture market share as competitor contract expires
2026 revenue
outlook increased
mFLUSIVA 2027
EU product
approvals
LATAM and APAC
partnerships
Intismeran
Four approved
products in the EU
Estimated 2027 TAM
(millions of doses)
Key milestone
timeline
Flu 65M
COVID 21M
RSV 4M
Sources: ECDC, IQVIA MIDAS, internal analysis
Europe includes EU, Switzerland, Norway, Iceland
2025 mRESVIA launch in Germany
2026 mNEXSPIKE approval mCOMBRIAX approval
2027 COVID market re-opens mNEXSPIKE launch Spikevax launch mCOMBRIAX launch mFLUSIVA approval+launch
19
© 2026 Moderna, Inc. All rights reserved.
Visuals: Four stacked product cards in the left column, each a white rounded-looking box with a coloured top band: (1) top band dark teal #085B81, Spikevax logo (red wave symbol inside a dark blue-grey hexagon, wordmark 'spikevax' in dark slate with TM mark) with grey subline 'COVID-19 Vaccine, mRNA'; (2) top band green #00837B, mNEXSPIKE logo (green wave in hexagon, wordmark in green) with grey subline 'COVID-19 Vaccine, mRNA'; (3) top band periwinkle blue #77A4D9, mRESVIA logo (red wave in blue hexagon, blue wordmark) with grey subline '(Respiratory Syncytial Virus Vaccine)'; (4) top band coral #F37877, mCOMBRIAX logo (coral wave in hexagon, coral wordmark with TM) with subline 'Influenza and COVID-19, mRNA Vaccine'. Middle column: a donut chart with no axes, titled by the column heading 'Estimated 2027 TAM (millions of doses)'. Donut segments clockwise from 12 o'clock: small navy #1E2846 segment (RSV, about 4%), red #E31837 segment (COVID, about 21 of 90 total, about 23%), large sky blue #3DB0E6 segment (Flu, about 65 of 90, about 72%). Donut hole is white with a centred grey-and-navy icon of three test tubes/vials with red caps. Below the donut is a legend table with three rows separated by thin grey rules: blue dot 'Flu' with value '65M' right-aligned in blue; red dot 'COVID' with value '21M' in red; navy dot 'RSV' with value '4M' in navy. Right column: a vertical timeline in light blue #3DB0E6 with a thick arrow line running down and a downward-pointing arrowhead at the bottom; three year markers on the line at left, each a circle with red outline: 2025 with red check mark, 2026 with red check mark, 2027 with red filled dot; each marker has a red bold year label at its left. Milestones attach by thin blue connector lines with blue dots to small round icon badges (light blue rings with rocket or document or bar-chart glyphs): 2025 rocket icon 'mRESVIA launch in Germany'; 2026 document icons 'mNEXSPIKE approval' and 'mCOMBRIAX approval'; 2027 bar-chart icon 'COVID market re-opens' (blue text), rocket icons 'mNEXSPIKE launch', 'Spikevax launch', 'mCOMBRIAX launch', 'mFLUSIVA approval+launch'. Sidebar icons, all grey #A2A2A4 monochrome line icons in grey filled circles (about 2.6% of width): growth bar chart with rising arrow (top), syringe (mFLUSIVA), blue EU stars-in-circle emblem on a blue #2AACE2 filled circle (EU item), handshake (LATAM and APAC), person with DNA helix icon (Intismeran). The tag bar is a pale blue #DFEAF5 rectangle with no border.
Slide 20
2027 growth driver / Developing long-term LATAM and APAC partnerships / Mexico / Taiwan / Five-year agreement for COVID vaccines signed in September 2026 with local manufacturer / Multi-year tender for COVID vaccines awarded in December 2025 / Meaningful long-term volume commitment, with annual minimum thresholds / Execution underway: Initial 1M doses shipped in September 2026 / Execution underway: Initial 4M doses shipped in September 2026 / Exploring similar multi-year partnerships globally / 2026 revenue outlook increased / mFLUSIVA 2027 / EU product approvals / LATAM and APAC partnerships / Intismeran / 20 / © 2026 Moderna, Inc. All rights reserved.
Visuals: Flag of Mexico (boxed, not cropped): three vertical bands, green (left), white (centre) with a coat-of-arms emblem, red (right). Flag of Taiwan (boxed, not cropped): blue canton in the upper left with a white sun emblem, red field. Sidebar icons, all thin white line-art on grey circles (inactive) or on a blue circle (active): 2026 revenue outlook icon (bar chart with rising arrow), mFLUSIVA 2027 icon (syringe), EU product approvals icon (circle of twelve stars, EU emblem), LATAM and APAC partnerships icon (two hands shaking, blue circle #2AACE2), Intismeran icon (person silhouette with hourglass). Bottom callout band contains a globe icon: a blue (#2AACE2) outline sphere with a vertical meridian and horizontal equator line, on the pale band. Bottom-right mosaic: a horizontal strip of six pale pink rectangles of varying widths, in tints of #F2C4CF to #FBE3E8, unevenly sized, no border. Thin divider lines are light grey hairlines.
Slide 21
2027 growth driver | Intismeran in adjuvant melanoma | Phase 3 clinical study reported positive results | 2026 revenue outlook increased | mFLUSIVA 2027 | EU product approvals | LATAM and APAC partnerships | Intismeran | 21 | © 2026 Moderna, Inc. All rights reserved. | Establishing INT as the standard of care in adjuvant melanoma | Meaningful and durable benefit | Phase 3 results show a 42% reduction in the risk of recurrence or death with intismeran + KEYTRUDA® vs. KEYTRUDA alone | Potentially curative | Opportunity to change the trajectory for patients with high-risk melanoma | Safety | Intismeran+KEYTRUDA has a manageable safety profile without potentiation of immune-related adverse events | RFS Primary Analysis: ITT | HR 0.58 [95% CI 0.45–0.75] | P < 0.001 (two-sided) | RFS (%) | Months | No. at risk | RFS Sensitivity Analysis: mITT | RFS (%) | 84.2% (95% CI 81.3–86.7) | 70.4% (95% CI 65.3–74.9) | HR 0.51 (95% CI 0.39–0.67) | N | Events, n (%) | Intismeran + pembrolizumab 726 116a (16.0%) | Placebo + pembrolizumab 365 106b (29.0%) | *31 patients in the intismeran + pembrolizumab arm were excluded from the mITT population due to AEs (n=13), recurrence (n=8), or other reason (n=10); RFS events occurred in 20 (64.5%) of the 31 patients who did not receive intismeran as planned. ¹15 patients in the placebo + pembrolizumab arm were excluded from the mITT population due to AEs (n=5), recurrence (n=4), or other reason (n=6); RFS events occurred in 5 (33.3%) of the 15 patients who did not receive placebo as planned. mITT: all randomized patients who received intismeran or placebo as assigned. RFS: time from randomization to the first occurrence of any recurrence or death from any cause. Data cutoff date: June 30, 2026 (median study follow-up: 24.6 mo). Presented by: Georgina V. Long, Melanoma Institute Australia. Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. | ESMO
Visuals: Two Kaplan-Meier survival charts and five-plus small icons. Chart 1 (top, RFS Primary Analysis: ITT): line chart, y-axis RFS (%) 0 to 100 in steps of 10, x-axis Months about 0 to 36 in steps of 6, green curve Intismeran + pembrolizumab labelled 82.2% (95% CI about 73.3–88.9) at about 24 months, blue curve Placebo + pembrolizumab labelled about 70.4% (95% CI about 65.3–74.9) at about 24 months; annotation HR 0.58 [95% CI 0.45–0.75], P < 0.001 (two-sided); a grey-headed table below the plot with columns N and Events, n (%) and rows Intismeran + pembrolizumab and Placebo + pembrolizumab, values blurred and only partly legible; a No. at risk row beneath the x-axis; a faint footnote block at the lower left is barely legible. Chart 2 (lower, RFS Sensitivity Analysis: mITT): line chart with y-axis RFS (%) 0 to 100 in steps of 10 and x-axis Months 0, 6, 12, 18, 24, 30, 35; green Intismeran + pembrolizumab curve labelled 84.2% (95% CI 81.3–86.7) at 24 months and ends near 84%; blue Placebo + pembrolizumab curve labelled 70.4% (95% CI 65.3–74.9) at about 24 months; no legend, colours are used as labels; annotation HR 0.51 (95% CI 0.39–0.67); table with columns N and Events, n (%): Intismeran + pembrolizumab 726, 116a (16.0%); Placebo + pembrolizumab 365, 106b (29.0%). No at risk row: Intismeran + pembrolizumab 726, 674, 638, 611, 133, 9, 0; Placebo + pembrolizumab 365, 333, 294, 275, 71, 2, 0 at months 0, 6, 12, 18, 24, 30, 35. A dashed vertical grey reference line at 24 months in both charts. Small ESMO logo bottom-right of chart 2. Icons: red upward-trend bar chart icon (blue bars, red arrow) beside 'Meaningful and durable benefit'; blue target with red star arrow beside 'Potentially curative'; blue outline shield with red check mark beside 'Safety'. Five grey circular navigation icons in the sidebar: revenue bar chart with rising arrow (2026 revenue outlook increased), syringe (mFLUSIVA 2027), EU stars circle (EU product approvals), handshake (LATAM and APAC partnerships), and person with DNA strand (Intismeran, active, in blue circle). Charts have soft grey drop shadows and are boxed rectangles, not cropped.
Slide 22
2027 growth driver
Intismeran: launch-ready infrastructure
The specialist capabilities and integrated ecosystem are in place to launch at scale
2026 revenue / outlook increased
mFLUSIVA 2027
EU product / approvals
LATAM and APAC / partnerships
Intismeran
Commercial and operational ecosystem
A high-science specialist commercial model and integrated / end-to-end service model
Commercial / partnership
Moderna and Merck / co-promote in the U.S.
Merck promotes / outside of the U.S.
Specialist / commercial model
HCP order / portal
mINT / engine
Purpose-built / manufacturing
Combines Merck’s field / infrastructure and oncology / expertise with dedicated / Moderna team
Simple, / streamlined / experience
Orchestrates / individualized / manufacturing
Designed to support / reliable, commercial- / scale production
Integrated capabilities designed to enable / a reliable, scalable launch on Day 1
22
© 2026 Moderna, Inc. All rights reserved.
Visuals: Four-column process graphic in the main area: each column has a light blue (#E8F4FC-like) filled circle about 14% of slide width in diameter containing a two-colour line icon. Column 1: three person outlines (one red centre person, one cyan left and one navy right) standing together. Column 2: a navy laptop outline with a red person silhouette on its screen and a cyan base line. Column 3: two gear outlines, one cyan at lower left and one red at upper right. Column 4: a red-and-navy outline of a factory building with a sawtooth roof, windows and a small red fan/vent detail. Thin blue-grey vertical separators sit between columns 1-2, 2-3 and 3-4, spanning about y 40.6% to 55.3%. Behind the four columns is a very faint pale grey-blue textured panel. Below the columns, a navy curly brace (about x 22.6% to 73.2%, y 76.3% to 81.3%) with its point facing down toward the takeaway line. Right column: a red outline map of the contiguous United States (no fill, thin red stroke) and a red outline globe with meridian and parallel lines (no fill). Left nav: five grey circular icons (about 6.5% width, grey fill with white line glyphs): revenue chart with rising arrow, syringe, EU stars ring, handshake, and a blue circle (#2AACE2) with a person and DNA helix glyph for Intismeran (the active item). Bottom-right: a horizontal strip of six pale pink rectangles of differing shades from light pink to dusty rose.
Slide 23
2027 growth driver / Intismeran: Eligible U.S. market / A meaningful U.S. eligible population with high recurrence risk and treatment gaps / High unmet need / ~1 in 10 / recur or die within a year / of adjuvant therapy 1 / ~50%+ / of first recurrences involve / distant metastases 2 / ~35-45% / of eligible Stage II patients / receive no adjuvant therapy / post-surgery 3 / ~22,000 / Patients eligible annually / in adjuvant melanoma * / *Phase 3 INTerpath-001 eligible population resected cutaneous melanoma Stage IIB-IV / Sources: 1. Eggermont et al., KEYNOTE-054. 2 Luke et al. 2025, KEYNOTE-716; 3 / Internal market research. / 2026 revenue / outlook increased / mFLUSIVA 2027 / EU product / approvals / LATAM and APAC / partnerships / Intismeran / 23 / © 2026 Moderna, Inc. All rights reserved.
Visuals: 1) Sidebar navigation icons (five grey circles, about 3.1% wide and 5.5% tall, left column at about x 6.2%): (a) line bar-chart with rising arrow icon, white line art on grey #A2A2A4 circle, for 2026 revenue outlook increased; (b) syringe icon, white on grey, for mFLUSIVA 2027; (c) ring of small stars (EU flag motif), white on grey, for EU product approvals; (d) handshake icon, white on grey, for LATAM and APAC partnerships; (e) person with DNA-strand icon, white on blue #2AACE2 circle, for Intismeran (the active item). 2) Central illustration (about 18.7% wide by 40.4% tall, starting at x 46.5%, y 28.9%): a simple line drawing of a woman's head, neck, shoulder and upper back in profile, facing left, drawn in light blue #2AACE2 strokes with darker blue #1E5FB4 accents on the shoulder and back contour; a red dotted circle (#E31837 dashed stroke) on the upper chest/back contains a small brown-outlined tumour-like blob. The illustration sits on a near-white #FBFBFD rectangle with no border, unboxed on the white background, not cropped. 3) Three right-column icons: (a) blue clock with a red curved arrow circling it (about 4.0% wide, x 72.8%, y 33.1%); (b) blue cell-network cluster of connected circles with red arrows pointing outward in all directions (about 5.7% wide, x 72.4%, y 50.2%); (c) small blue person figure linked by a red double-headed dotted arrow to a blue medical cross (about 5.0% wide, x 72.0%, y 69.3%). 4) Decorative block bottom-right (x 86.6%, y 92.2%, 12.2% by 4.9%): five adjacent flat pink rectangles of differing tints, left to right about #F3D5DC, #F0C8D2, #E8BCC6, #F7DEE4, #E9CDD3, with no gaps. 5) Vertical divider line at x 67.7%, from y 23.6% to 82.2%, thin grey #BFBFBF about 0.1% wide. No photographs.
Slide 24
Balancing near-term / growth with long-term / R&D innovation / 24
Visuals: One decorative image: a pale light-blue abstract ribbon or wave-like swoosh occupying the right side of the slide (approximately x 27.9% to 100%, full height), curving from the upper right edge down toward the bottom centre-right. It is soft-edged, low-contrast, rendered in very pale sky blue with lighter highlights and a subtle translucent texture, with no people, objects or text. It is placed as a full-height image covering the right portion, not cropped to a box, and blends into the light background. Composition: the ribbon sweeps diagonally from top-right to bottom, framed by the slide's right edge.
Slide 25
2027-2030: Driving financial sustainability while investing in the
next generation of growth
Infectious disease vaccines
Self-funded growth
Disciplined reinvestment of commercial cash flows in infectious disease vaccine pipeline
Opportunities
Lyme disease
Potential Phase 2/3 trial
EBV (mRNA-1189)
Potential Phase 3 trial
Other potential future investments
Potential Phase 2/3 trials
25
© 2026 Moderna, Inc. All rights reserved.
Visuals: Three small line icons in a row above the three opportunity columns: a tick/spider-like arasite icon in red outline with a blue body (left of 'Lyme disease', about 85 by 74 pixels scale, at x 11.8%, y 46.8%), a virus-particle icon in red outline with a blue centre (left of 'EBV (mRNA-1189)', at x 33.5%, y 47.3%), and a microscope icon with red outline and blue accents (left of 'Other potential future investments', at x 55.8%, y 47.2%). A chevron banner: left segment is a pale pink rectangle with a right-pointing arrow tip, right segment is a solid red chevron with a notched left edge and pointed right tip. Bottom-right a decorative strip of six pink squares of varying tints (about 6 by 2 pixel scale block at x 86.6%, y 92.2%). No photographs or charts.
Slide 26
2027-2030: Driving financial sustainability while investing in the / next generation of growth / Infectious disease vaccines / Self-funded growth / Intismeran / Balance sheet-funded growth / Accelerated investment to drive near-term revenue growth and long-term profitability / Investment opportunities / Intismeran: commercialization / commercial, medical, manufacturing / Intismeran: new indications / Clinical development / 26 / © 2026 Moderna, Inc. All rights reserved.
Visuals: Two pairs of chevron-shaped horizontal bands. Top pair: a light pink (#FDECEF) rectangle with red text 'Infectious disease vaccines' flowing into a red (#E31837) right-pointing chevron reading 'Self-funded growth'. Bottom pair: a light lavender-blue (#D4DAEC) rectangle with navy text 'Intismeran' flowing into a navy (#1E2846) right-pointing chevron reading 'Balance sheet-funded growth'. Two identical small icons, each a dark navy outline of a person silhouette beside a blue double-helix DNA strand, sit to the left of the two investment opportunity labels. Bottom-right decorative strip of six adjacent vertical rectangles in pale pinks (about #F5CDD5, #EFC3CC, #E9BCC6, #F7D5DC, #EDC6CE, #E5BFC8) at about 86.6% x, 92.2% y, 12.2% wide and 4.9% high, with no text on it.
Slide 27
2027-2030: Driving financial sustainability while investing in the next generation of growth
Infectious disease vaccines
Self-funded growth
Intismeran
Balance sheet-funded growth
mRED
Balance sheet-funded innovation
Disciplined, multi-year investment in cutting-edge R&D
Investment opportunities
Cancer Antigen Therapies
Clinical development across trials
T cell engagers
Clinical development and research
Future modalities
Research & development
27
© 2026 Moderna, Inc. All rights reserved.
Visuals: Three horizontal chevron bars. Row 1: pale pink #FDECEF band with the label Infectious disease vaccines in red, joined to a red #E31837 right chevron labelled Self-funded growth in white. Row 2: pale lavender #D4DAEC band with the label Intismeran in navy, joined to a navy #1E2846 right chevron labelled Balance sheet-funded growth in white. Row 3: pale blue #E5F5FB band with the label mRED in blue, joined to a bright blue #2AACE2 right chevron labelled Balance sheet-funded innovation in white. Each right chevron has a pointed tip on its right and a notched left edge that interlocks with the band. Bottom-left of the lower area: a cancer-antigen icon, a T-cell engager icon and a lightbulb icon, all drawn in navy and blue outline line art. Bottom-right: a strip of five adjacent rectangles in pale pinks (lightest to mid pink) forming a decorative block.
Slide 28
Manufacturing
Juan Andres
Chief Operating Officer
28
© 2026 Moderna, Inc. All rights reserved.
Visuals: Decorative photograph/illustration occupying the right side and full slide behind the panel: soft pale blue translucent ribbon-like waves sweeping diagonally from lower left to upper right over an off-white (#F2F6F9) ground, with no people or objects. A white circular badge (about 6% wide, 12.5% tall at left-top of title) contains a red (#E31837) circle outline with a red sine-like curve and three short blue (#2AACE2) vertical tick marks beneath the curve, representing a manufacturing/process icon. A moderna logo (red wordmark with a row of blue dashes beneath) sits bottom right, about 14.8% wide. A thin blue arc (#2AACE2) forms the curved boundary between the navy panel and the wave image. A short red (#E31837) horizontal rule sits under the title.
Slide 29
Our global infectious disease vaccines manufacturing network
Sites across North America, Europe and Australia supporting global supply
Harwell
UNITED KINGDOM
Laval
CANADA
Norwood
UNITED STATES
Contract manufacturing partner
Clayton
AUSTRALIA
29
© 2026 Moderna, Inc. All rights reserved.
Visuals: World map drawn as a flat light-blue (#D4EEF9) continent silhouette with thin white country borders, no labels, no graticule. Four red (#E31837) pin callouts: each has a solid red dot marker on the site location with a thin red leader line running up or sideways to a text label. Laval (Canada): dot on the eastern Canada/US border area near the Great Lakes region, leader line running straight up from the dot, label above-left of the line end. Harwell (United Kingdom): dot on southern England, leader line running straight up from the dot, label to the right of the line top. Norwood (United States): dot on the US East Coast near New York/Pennsylvania, leader line running right-to-left as an elbow (horizontal then diagonal up-right to the dot), label to the left. Clayton (Australia): dot on southeastern Australia, leader line running straight up from the dot, label to the right of the line top. Legend item: a small grey (#7F7F7F) filled circle at the left of the grey text 'Contract manufacturing partner', placed over the Western Europe/North Africa area of the map, not a site pin, marking a contract manufacturing partner.
Slides 30 to 183 continue in the full text file.
Download this deck
The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.
Preparing a results presentation or business update of your own? The SlideDeck Co Standard Deck is a slide library for business reviews, updates and plans.






